Actively Recruiting
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Led by The Affiliated People's Hospital of Ningbo University · Updated on 2024-07-25
99
Participants Needed
16
Research Sites
121 weeks
Total Duration
On this page
Sponsors
T
The Affiliated People's Hospital of Ningbo University
Lead Sponsor
F
First Affiliated Hospital of Zhejiang University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem cells in patients with newly diagnosed multiple myeloma (NDMM). A total of 99 NDMM patients will be enrolled and randomly assigned to receive either the EAP regimen or the GC regimen (cyclophosphamide+ G-CSF) to mobilize hematopoietic stem cells. Subsequently, the mobilization effects and adverse reactions of all patients will be observed and compared.
CONDITIONS
Official Title
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients newly diagnosed with multiple myeloma
- Eligible for autologous stem cell transplantation (ASCT)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy of at least 3 months
- Ability to understand the study protocol and provide informed consent
You will not qualify if you...
- Cardiac function class II or higher or ejection fraction below 40%
- Serum direct bilirubin above twice the upper limit of normal
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than three times the upper limit of normal
- Serum creatinine clearance rate 30% or less
- Presence of active infection
- Previous hematopoietic stem cell mobilization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Dongyang People's Hospital
Dongyang, Zhejiang, China
Actively Recruiting
2
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Actively Recruiting
3
Tongde Hospital of Zhejiang Province
Hangzhou, Zhejiang, China
Actively Recruiting
4
Huzhou central hospital
Huzhou, Zhejiang, China
Actively Recruiting
5
The First Hospital of Jiaxing
Jiaxing, Zhejiang, China
Actively Recruiting
6
Jinhua Municipal Central Hospital
Jinhua, Zhejiang, China
Actively Recruiting
7
Jinhua People's Hospital
Jinhua, Zhejiang, China
Actively Recruiting
8
Lishui Central Hospital
Lishui, Zhejiang, China
Actively Recruiting
9
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China
Actively Recruiting
10
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, China
Actively Recruiting
11
Shaoxing People's Hospital
Shaoxing, Zhejiang, China
Actively Recruiting
12
Shaoxing Second Hospital
Shaoxing, Zhejiang, China
Actively Recruiting
13
Taizhou Central Hospital
Taizhou, Zhejiang, China
Actively Recruiting
14
Taizhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
Actively Recruiting
15
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Actively Recruiting
16
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Actively Recruiting
Research Team
Y
Ying Lu
CONTACT
P
Peipei Ye
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here